Adel Shaheen
Cardiovascular Disease · Lima, OHNPI 1801969985
Payments from drug & device makers
Across 96 payments — averaging $28.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- AstraZeneca$359
- Novartis$190
- Amgen$142
- Amarin Pharma, Inc.$112
- Boehringer Ingelheim$87
- plus $617 from 17 others
What the payments were for
- Consulting fees$151%
- Travel & lodging$73327%
- Food & beverage$1,97672%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 6 | $1,231 |
| AstraZeneca | 21 | $359 |
| Novartis | 12 | $190 |
| Amgen | 8 | $142 |
| Amarin Pharma, Inc. | 6 | $112 |
| Boehringer Ingelheim | 5 | $87 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $85 |
| Johnson & Johnson | 5 | $83 |
| Merck | 4 | $69 |
| Bayer | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Regeneron Healthcare Solutions, Inc. | 3 | $44 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Pfizer | 2 | $33 |
| Penumbra, Inc. | 2 | $29 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Cardiovascular Systems Inc. | 1 | $16 |
| Z-medica, LLC | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,192
How this compares
$2,738 in reported general payments places this provider in the 55th percentile of 827 cardiovascular disease providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $169,500 |
| EntrestoSacubitril/Valsartan | 85 | $101,831 |
| FarxigaDapagliflozin Propanediol | 41 | $43,728 |
| XareltoRivaroxaban | 25 | $36,712 |
| BrilintaTicagrelor | 17 | $19,454 |
| JardianceEmpagliflozin | 18 | $17,073 |
| Potassium Chloride | 102 | $4,232 |
| Metoprolol Succinate | 232 | $3,830 |
| Bumetanide | 97 | $3,286 |
| Ranolazine ErRanolazine | 33 | $3,254 |
| ClopidogrelClopidogrel Bisulfate | 220 | $3,014 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 78 | $2,653 |
| Atorvastatin Calcium | 263 | $2,577 |
| Rosuvastatin Calcium | 178 | $2,558 |
| Losartan Potassium | 217 | $2,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $169,500136 claims |
| NovartisEntresto | $190 | $101,83185 claims |
| AstraZenecaFarxiga, Brilinta | $359 | $63,18158 claims |
| Johnson & JohnsonXarelto | $83 | $36,71225 claims |
| Boehringer IngelheimJardiance | $87 | $17,07318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Lima
- Eliyazar GaddamLima$519K
- Samir KapadiaCleveland$11.1M
- Steven NissenCleveland$5.3M
- Milind DesaiCleveland$5M
- Abraham LincoffCleveland$3.6M
- Carlos HubbardCleveland$3.1M
- Guilherme AttizzaniCleveland$2.8M
- Wai Hong TangCleveland$2.2M
- Bhola RamaMarion$2.1M
- Mazen HannaCleveland$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.